There has been much debate and controversy about the safety and efficacy of the topical use of tranexamic acid in primary total knee arthroplasty (TKA). The purpose of this study was to perform a meta-analysis to evaluate whether there is less blood loss and lower rates of transfusion after topical tranexamic acid administration in primary TKA. A systematic review of the electronic databases PubMed, CENTRAL, Web of Science, and Embase was undertaken. All randomized, controlled trials and prospective cohort studies evaluating the effectiveness of topical tranexamic acid during primary TKA were included. The focus of the analysis was on the outcomes of blood loss results, transfusion rate, and thromboembolic complications. Subgroup analysis was performed when possible. Of 387 studies identified, 16 comprising 1421 patients (1481 knees) were eligible for data extraction and meta-analysis. This study indicated that when compared with the control group, topical application of tranexamic acid significantly reduced total drain output (mean difference, -227.20; 95% confidence interval, -347.11 to -107.30; P<.00001), total blood loss (mean difference, -311.28; 95% confidence interval, -404.94 to -217.62; P<.00001), maximum postoperative hemoglobin decrease (mean difference, -0.73; 95% confidence interval, -0.96 to -0.50; P<.00001), and blood transfusion requirements (risk ratios, 0.33; 95% confidence interval, 0.24 to 0.43; P=.14). The authors found a statistically significant reduction in blood loss and transfusion rates when using topical tranexamic acid in primary TKA. Furthermore, the currently available evidence does not support an increased risk of deep venous thrombosis or pulmonary embolism due to tranexamic acid administration. Topical tranexamic acid was effective for reducing postoperative blood loss and transfusion requirements without increasing the prevalence of thromboembolic complications. [Orthopedics. 2015; 38(11):e1007-e1016.] The authors are from the
T otal knee arthroplasty (TKA) is one of the most common surgeries in orthopedic practice and is associated with high rates of postoperative blood loss and transfusion. Reported amounts of blood loss have ranged from 1450 to 1790 mL, [1] [2] [3] necessitating allogeneic blood transfusion in 10% to 38% of patients. 4, 5 However, blood transfusion is not a zero-risk procedure. Potential hazards include hemolysis, infection, immunosuppression, transfusion-related acute lung injury, and even death. 6, 7 Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that binds to the lysine binding site of plasminogen and blocks the binding of plasminogen to the fibrin surface. Thus, plasminogen activation is prevented and fibrinolysis is delayed. 8 Several meta-analyses have shown that intravenous administration of TXA reduced postoperative bleeding and the need for transfusion in TKA. 9, 10 However, concerns remain over the risk of thromboembolic complications after systemic administration. 11 In light of the safety concerns with intravenous administration, there has been a growing interest in the topical use of TXA for prevention of bleeding in major orthopedic procedures. Topical application leads to 70% lower systemic absorption and therefore may be a safer alternative to giving it systemically. 12 In addition, topical TXA application has the advantage of inducing partial microvascular hemostasis by stopping fibrin clot dissolution in the affected area. Once topically applied, TXA is rapidly absorbed and maintains a biological half-life of approximately 3 hours within joint fluid. 1, 13 Topical use of TXA can markedly reduce postoperative total drain output. 14, 15 However, it is still controversial whether the topical use of TXA can reduce transfusion rates. Eight randomized, controlled trials (RCTs) [14] [15] [16] [17] [18] [19] [20] [21] and 2 prospective cohort studies (PCSs) 22, 23 evaluating outcomes of topical TXA were published in 2013 and 2014. The current authors performed an updated meta-analysis to investigate whether topical application of TXA makes a difference in terms of (1) blood loss results, including total drain output, total blood loss, and maximum postoperative hemoglobin (Hb) decrease; (2) transfusion requirements; and (3) thromboembolic complications, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
Materials and Methods
The methods adopted for this review were based on the recommended PRISMA checklist guidelines.
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Search Strategy
The authors searched electronic databases, including PubMed, CENTRAL (Cochrane Controlled Trials Register), Web of Science, and Embase, for relevant studies published between the time of the establishment of these databases and October 2014. The following search terms were used to maximize search specificity and sensitivity: (total knee arthroplasty OR total knee replacement OR TKA OR TKR) AND tranexamic acid. The bibliographies of identified articles, including relevant reviews and meta-analyses, were manually searched for potential eligible reports. In addition, the Google search engine was used to search for additional trials. There were no restrictions in terms of publication date or language.
Eligibility Criteria
Study selection was performed according to the following inclusion criteria: (1) RCT or PCS; (2) participants underwent primary TKA; (3) interventions included topical (intra-articular) administration of TXA; (4) results of a placebo (control) group were reported; and (5) reported outcomes included postoperative total drain output, total blood loss, maximum postoperative Hb decrease, number of patients receiving blood transfusion, and incidence of DVT and PE. Conference abstracts were included if sufficient data were provided. Studies with cadaver and artificial models were excluded, as were those that included patients with bleeding disorders.
Data Extraction
After exclusion of duplicates, 2 reviewers (H.W., Y.Z.) independently screened the titles and abstracts of identified studies. Most citations could be excluded on the basis of information provided by their title or abstract. Otherwise, the full article was obtained and carefully scrutinized by the 2 reviewers. If necessary, the authors attempted to contact the author of the original report to obtain further details. Any disagreement was resolved by consensus.
The following data were extracted: (1) demographic data of participants, including age, sex, indication for TKA, location of study, length of follow-up, and whether they underwent unilateral or bilateral TKA; (2) general surgical information, including surgical approach, method of administration, transfusion criteria, and whether conventional TKA (Con-TKA) or computer-assisted TKA (CAS-TKA) was performed; and (3) number of patients receiving blood transfusion; blood loss results, including total drain output, total blood loss, and maximum postoperative Hb decrease; and thromboembolic complications, including DVT and PE.
Outcome Measures
The primary outcome was the proportion of patients who were transfused with allogeneic blood, autologous blood, or both. The secondary outcomes were total drain output, total blood loss, maximum Hb decrease, and thromboembolic complications. Subgroup analysis was also performed based on the topically administered dose (low dose [<1. 
Study Quality
The methodological quality of the RCTs was assessed independently. Study n Feature Article quality was assessed using the Jadad 25 5-point scale, which includes 2 questions: one on randomization and masking and one on the reporting of dropouts and withdrawals. Studies achieving 3 or more points (from a maximum of 5) were considered to be of high quality. Discrepancies were resolved by consensus after discussion, and a third reviewer was consulted if necessary.
Statistical Analysis
Dichotomous outcomes (transfusion rate, complication rates) were expressed as risk ratios (RRs) with 95% confidence interval (CIs). Continuous outcomes (total drain output, total blood loss, and maximum Hb decrease) were expressed as mean differences (MDs) and respective 95% CIs. To summarize findings across the trials, a P value less than .05 was considered statistically significant; outcomes of the meta-analysis were assessed with RevMan version 5.2 statistical software (The Nordic Cochrane Center, The Cochrane Collaboration). Statistical heterogeneity was tested using the chi-square test and I 2 statistic. A value of less than 0.1 with the chi-square test was considered suggestive of statistical heterogeneity. Heterogeneity was also assessed by the I 2 statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance. 26 An I 2 statistic value of more than 50% was considered to indicate substantial heterogeneity. 27 Depending on the heterogeneity, meta-analysis was performed using fixed-effects or random-effects models. When there was no statistical evidence of heterogeneity, a fixed-effects model was adopted; otherwise, a random-effects model was chosen. Publication bias was tested using funnel plots. Figure 1 shows details of the identification, inclusion, and exclusion of studies. In the initial search, the authors identified 387 potentially relevant studies. Of these, the authors included 16 clinical trials with 1421 patients (1481 knees) in the meta-analysis. Classification of the remaining studies resulted in a total of 14 RCTs 12,14-19,21,28-33 and 2 PCSs. 22, 23 The complete manuscripts for 2 studies could not be obtained, and the relevant data for analysis were extracted from the respective abstracts. 28, 29 Five reports included 2 treatment groups (based on different doses of topically applied TXA) compared with a control group. 12, 14, 21, 28, 29 These groups were analyzed separately, ultimately resulting in 21 component studies for the meta-analysis. Of the included studies, all articles were in English and were published after 2009. Characteristics of the included studies are shown in Table  1 and Table 2 . Most trials were small, with participant numbers ranging from 20 29 to 159. 23 However, trials were relatively well designed, and Jadad scores were generally high. Patient ages ranged from 61 23 to 73.5 years, 30 and the doses of TXA ranged from 250 14, 31 to 3000 mg. 12, 21, 23, 28, 29, 33 All patients had undergone primary TKA. In the current authors' meta-analysis, RCTs and PCSs were analyzed separately.
results
Search Results
Quality Assessment
Jadad scores of the 14 RCTs are summarized in Table 1 . The total scores show that the quality of the 12 trials (84.6%) is high, with a minimum of 2 points 19,30 and a maximum of 5 points. 12, 14, 16, 31, 32 Meta-analysis of Randomized,
Controlled Trials
Total Drain Output. A total of 7 component studies (527 patients) provided Blood Transfusion Requirements. A total of 14 component studies (1230 patients) provided data on the number of patients who needed transfusion. In the TXA group, transfusions were required in 48 (7.8%) of 612 patients; in the control group, they were required in 153 (24.8%) of 618 patients. The summarized estimate of effect size indicated a significantly lower (Figure 2 ). There was low statistical heterogeneity between studies (P=.14; I 2 =30%). Thromboembolic Complications. All component studies (1358 patients) provided data on thromboembolic complications. No symptomatic DVT was reported in 10 studies and no symptomatic PE was reported in 14 studies in both treatment and control groups. Of the 668 patients in the TXA group, 15 (2.2%) cases of DVT and 2 (0.3%) cases of PE were reported. In the control group (n=690), 21 (3.0%) cases of DVT and 6 (0.9%) cases of PE were recorded. There was no statistically significant difference between the groups in the number of patients with DVT (RR, 0.78; 95% CI, 0.42 to 1.44) and PE (RR, 0.49; 95% CI, 0.14 to 1.69) in the absence of statistical heterogeneity (P=.81; I 2 =0% and P=.97; I 2 =0%, respectively). Subgroup Analysis. To eliminate the heterogeneity, 14 RCTs were under subgroup analysis based on the topically administered dose, surgical protocol (CAS-TKA or Con-TKA), and timing of drain clamping. The primary significant result of this review was transfusion rate. In subgroup analysis of TXA dose, 6 component studies were low-dose (<1.5 g) and 8 were high-dose (≥1.5 g). In subgroup analysis of surgical protocol, 3 component studies reported the results of CAS-TKA and 11 component studies reported Con-TKA. In subgroup analysis of timing of drain clamping, 6 component studies were assigned to the short-time subgroup (<2 hours) and 8 component studies were assigned to the long-time (≥2 hours) subgroup. There were significant differences in all analyses confirming that the incidence of transfusion was lower in the TXA group. Table 3 shows the results of the meta-analysis and subgroup analysis of the cumulative data from these 14 RCTs.
Meta-analysis of Prospective Cohort Studies
Two trials were PCSs and were analyzed separately. There were 160 patients in the TXA group and 59 patients in the control group. None of 130 patients in the TXA group and 3 of 29 patients in the control group needed transfusion. The TXA group had lower transfusion rates compared with the control group. Heterogeneities for each outcome are presented in Table 4 . The MDs for total blood loss and maximum Hb decrease were -231.00 and -0.61, respectively, showing statistical significance between the groups (P=.01 and .0001, respectively) (Table 4). No symptomatic thromboembolic event was reported in either of the 2 PCSs. With only 2 PCSs included, no subgroup analysis was performed.
discussion
The current authors' analysis shows that, in the overall comparison or subgroup analysis, topically administered TXA is effective for reducing the total drain output, total blood loss, maximum Hb decrease, and blood transfusion, without increasing the incidence of thromboembolic complications.
Total knee arthroplasty may cause significant perioperative bleeding because of the large exposed surface of cancellous bone and activation of local fibrinolysis, which is further enhanced by tourniquet release at the end of the procedure. 34 Thus, many patients undergoing TKA, particularly those older than 65 years, are at risk for anemia. Postoperative anemia can be an important problem that is associated with adverse effects, including increased mortality and morbidity 35 and a longer hospital stay due to the associated need for blood transfusion. 36, 37 Tranexamic acid was introduced with the aim of reducing postoperative bleeding and transfusion rate.
The efficacy of TXA administered intravenously for preventing blood loss has been established in many high-quality clinical trials and meta-analyses. 19, 33, [38] [39] [40] Furthermore, several recent studies have reported that topical application of TXA is equally as effective as or even more effective than the intravenous administration of TXA. 19, 21, 32, 41, 42 Theoretically, topically administrated TXA may be advantageous because it can directly target the source of bleeding 43 with minimal systemic absorption.
In the current study, topical application of TXA reduced blood loss by a mean volume of -311.28 mL (95% CI, -404.94 to -217.62) compared with the control group. However, the magnitude of this benefit is uncertain because of the significant heterogeneity in the findings. Maximum postoperative Hb decrease in the TXA group was decreased by approximately 0.73 g/dL. It seems that the observed magnitude does not reach the level of major clinical importance. However, 48 (7.8%) of 612 patients in the TXA group and 153 (24.8%) of 618 patients in the control Subgroup analysis suggested that in the high-dose TXA subgroup, the reduction of total blood loss was consistent and large. However, there were no significant differences in transfusion rate between the high-dose subgroup (RR, 0.34; 95% CI, 0.24 to 0.49) and low-dose subgroup (RR, 0.30; 95% CI, 0.19 to 0.48). Given the small numbers of patients involved, these findings require further confirmation. Theoretically, compared with Con-TKA, CAS-TKA should reduce blood loss because an intramedullary femoral guide was not necessary. 44 The current meta-analysis confirmed this point. Due to different drain clamping times, tissue contact time of TXA varied in many trials. In the long-time subgroup, the tissue contact time of the TXA subgroup was relatively longer compared with that in the short-time subgroup. However, there was no significant difference in transfusion rate between the 2 subgroups.
Theoretically, TXA carries a risk of thrombosis, although this has not been proven clinically. However, the current meta-analysis demonstrated no increased risk of DVT or PE. Interestingly, there were lower rates of DVT and PE in the TXA group than in the control group (2.2% vs 3.0% and 0.3% vs 0.9%, respectively). As reported by Alshryda et al, 45 TXA may reduce the risk of thrombosis by reducing the need for transfusion, which is a thrombogenic intervention. Nonetheless, uncertainty remains because of differences in DVT and PE screening. Many studies have evaluated only symptomatic DVT and PE without evaluating asymptomatic DVT and PE. Although not The limitations of this meta-analysis include the following. First, transfusion triggers and surgical techniques were not consistent among the studies. This may account for the clinical and statistical heterogeneity of these studies in the meta-analysis. To eliminate heterogeneity, subgroup analysis was performed. Second, functional outcomes or quality of life outcome measures could not be addressed because of a lack of relevant data. Finally, most trials included in this metaanalysis excluded high-risk patients, such as patients with cardiovascular disease, previous DVT events, and renal dysfunction. Thus, the results should be interpreted with caution. The authors were unable to reach a definite conclusion about the safety of TXA.
conclusion
This meta-analysis of currently available evidence indicates that topically administered TXA in primary TKA significantly reduces total drain output, total blood loss, maximum postoperative Hb decrease, and blood transfusion without an apparent increase in thromboembolic complications in patients without risk factors. However, studies with more patients and better-designed methods are needed to establish the benefits and risks of TXA in primary TKA.
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